ESMO Congress 2026Developing

exatecan

4 reports2 sourcesupdated 3 hours ago

Start here

Report excerpt

At the 2026 ESMO congress, Innovent announced in a late-breaking abstract that the international multicenter phase 3 G-HOPE-001 study of the CLDN18.2 ADC IBI343 in gastric cancer met both primary endpoints of progression-free survival and overall survival.

Excerpted from mp.weixin.qq.com

Coverage timeline

Follow the coverage to see the different angles.

Oct 26

05:02
x.com
MRG007 (CDH17 ADC) #ESMO26
04:57
x.com
MRG007 (CDH17 ADC) #ESMO26

Oct 24

15:27
x.com
Puzzling to see cathepsin B (CTSB) enrichment in Mo-Rez responders, given that the GGFG linker is a substrate of cathepsin L, not B.

Oct 23

20:40
mp.weixin.qq.com
Innovent Announces at 2026 ESMO LBA That IBI343 Met PFS and OS Dual Primary Endpoints in Phase 3 G-HOPE-001 Gastric Cancer Study
At the 2026 ESMO congress, Innovent announced in a late-breaking abstract that the international multicenter phase 3 G-HOPE-001 study of the CLDN18.2 ADC IBI343 in gastric cancer met both primary endpoints of progression-free survival and overall survival.

Heat trend for this story

Heat now 11·Peak in the comparable set 12 (Oct 26 06:00)·Change over 24h in the comparable set +206%·Participants now 2

Participants counted2

Heat over time

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.